HSX:LSEHiscox Ltd Analysis
Data as of 2026-03-11 - not real-time
£1,474.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Hiscox Ltd (HSX.L) is trading at 1,474 p, comfortably above its 20‑day SMA (1,475.6) and 50‑day SMA (1,463.8) while staying well above the 200‑day SMA (1,359.6), indicating a sustained bullish trend despite a neutral RSI of 49.3. Fundamentally, the insurer posts a solid 4.7% revenue growth, a healthy operating margin of 22% and a ROE of 15.8%, while its PE of 11.3 is well below the industry average of 17.3, suggesting relative undervaluation. Recent material news – a $300 million share buy‑back and earnings that beat expectations – has already lifted the stock 5.7%, reinforcing investor confidence in capital return and earnings momentum.
The dividend yield of 2.53% with a modest 25% payout ratio, strong cash position (≈£1 bn) versus debt (£0.84 bn), and an upside potential of roughly 8% per the DCF model support a favorable risk‑adjusted profile. However, a 30‑day volatility of 27% and a bearish MACD histogram signal short‑term caution, making the stock attractive for disciplined investors who can tolerate moderate price swings.
The dividend yield of 2.53% with a modest 25% payout ratio, strong cash position (≈£1 bn) versus debt (£0.84 bn), and an upside potential of roughly 8% per the DCF model support a favorable risk‑adjusted profile. However, a 30‑day volatility of 27% and a bearish MACD histogram signal short‑term caution, making the stock attractive for disciplined investors who can tolerate moderate price swings.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Share buy‑back program signaling confidence and potential price support
- Current price near strong technical support at 1,420 p
- Increasing volume confirming buying interest
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Stable earnings growth and attractive dividend yield
- PE advantage versus peers but MACD bearish divergence
- Potential for earnings acceleration from specialty lines
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation metrics (low PE, DCF upside) and favorable analyst targets
- Strong balance sheet with low debt‑to‑equity and sustainable dividend policy
- Resilient business model across diversified insurance segments
Key Metrics & Analysis
Financial Health
Revenue Growth4.70%
Profit Margin15.01%
P/E Ratio11.3
ROE15.82%
ROA4.23%
Debt/Equity21.27
P/B Ratio162.2
Op. Cash Flow£72.8M
Free Cash Flow£2.3B
Industry P/E17.3
Technical Analysis
TrendBullish
RSI49.3
Support£1,420.00
Resistance£1,560.50
MA 20£1,475.60
MA 50£1,463.76
MA 200£1,359.58
MACDBearish
VolumeIncreasing
Fear & Greed Index76.34
Valuation
Fair Value£12,375.42
Target Price£1,591.02
Upside/Downside7.94%
GradeUndervalued
TypeBlend
Dividend Yield2.53%
Risk Assessment
Beta0.26
Volatility27.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.